Last edition
News about
EMA Recommends Approval of Datroway for First-Line Treatment of Triple-Negative Breast Cancer
AstraZeneca and Daiichi Sankyo have received a positive recommendation from the European Medicines Agency's CHMP for Datroway as a first-line treatment for unresectable or metastatic triple-negative breast cancer in patients who are not eligible for immunotherapy, supported by Phase 3 trial results demonstrating improved survival and disease control.
Government Simplifies Drug Import Rules for Testing and Analysis
The Government has proposed amendments to the Drugs Rules, 1945, introducing an acknowledgement-based system to simplify the import of drugs for examination, testing, analysis, and non-clinical research.
Zydus Lifesciences and Sunshine Healthcare Form JV to Boost Pharma Manufacturing in Sri Lanka
Zydus Lifesciences and Sunshine Healthcare launch a Joint Venture (JV) to develop a pharma manufacturing facility at BOI Horana, strengthening Sri Lanka’s supply of quality medicines.
Lupin Receives US FDA Tentative Approval for Enzalutamide Tablets
Lupin has received tentative US Food and Drug Administration (FDA) approval for Enzalutamide tablets in 40 mg, 80 mg, 120 mg, and 160 mg strengths.
CHMP Recommends Lilly's Jaypirca for CLL Treatment in EU
CHMP has recommended Lilly’s Jaypirca (pirtobrutinib) for EU approval in adults with chronic lymphocytic leukemia (CLL), potentially expanding its use across all lines of therapy.
The rise of GLP-1 therapies has transformed diabetes and obesity treatment. Following semaglutide patent expiry in India in March 2026, multiple companies entered the market simultaneously. Pharma Industrial India spoke with industry leaders about the opportunities, challenges, and future of this rapidly evolving therapeutic segment.
BDR Pharma Launches Xatronem-AV to Combat Multidrug-Resistant Gram-Negative Infections
BDR Pharma introduces Xatronem-AV, a next-generation antibacterial therapy for serious multidrug-resistant Gram-negative infections.
US FDA Approves Pfizer's Ibrance for Maintenance Treatment of HR+, HER2+ Metastatic Breast Cancer
FDA approval makes Ibrance the first CDK4/6 inhibitor indicated for HR+ metastatic breast cancer regardless of HER2 status.
Lilly Completes Acquisition of Centessa to Advance Sleep Disorder Therapies
Lilly expands its neuroscience portfolio with the acquisition of Centessa Pharmaceuticals to accelerate treatments for narcolepsy and related sleep disorders.
NeuroSense Reports Positive Phase 2 Biomarker Results for PrimeC in Alzheimer's Disease Trial
PrimeC shows encouraging biomarker activity in Phase 2 Alzheimer’s study, supporting its potential as a multi-target therapy for neurodegenerative diseases.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy